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BCR-ABL fusion genes and laboratory findings in patients 




Background: A specific chromosomal abnormality, the Philadelphia chromosome (BCR-
ABL fusion), is present in all patients with chronic myeloid leukemia (CML). The b2a2 
and b3a2 fusion mRNAs encode p210 fusion protein p210 and e1a2 encode p190. The aim 
of this study was to evaluate the frequency of BCR-ABL fusion transcript variants in 
Northeast of Iranian CML patients and to compare the laboratory results of our patients. 
Methods: This study was conducted in 85 peripheral blood and bone marrow samples of 
CML patients. Ribonucleic acid (RNA) was extracted by a commercial kit, RT- PCR for 
identifying BCR-ABL fusions was carried out by using designed primers and the PCR 
products were electrophoresed in agarose gels. Finally, statistical analysis was performed 
for variant frequency identification and their comparison was performed. 
Results: All patients examined were positive for BCR/ABL rearrangement. Fusion of b3a2 
was detected in 53 (62.35%) patients, b2a2 in 25 (29.41), e1a2 in 1 (1.17%) and 
coexpression of b3a2 and e1a2 in 6 (7.05%) patients. There were significant differences 
between the mean age in patients with b3a2 positive ( 44.07 years) and in b3a2 negative 
group (50.35 years) however, no significant differences were seen between sex and b2a2 
(P=0.61), b3a2 (P=0.79) and e1a2 (P=0.20). 
Conclusions: This study showed higher frequency b3a2 than b2a2 and e1a2 transcripts in 
CML patients in Northeast Iran and there was no association between e1a2 transcripts 
frequencies and monocytosis in peripheral blood. 
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CML (chronic myeloid leukemia) or chronic granulocytic leukaemia is one of the 
myeloproliferative neoplasms (MPN) characterized by proliferation of a pluripotential 
stem cell that can differentiate along the granulocytic lineage and is consistently associated 
with the BCR-ABL1 fusion gene (1). It accounts about 15% of all leukemia cases (2). The 
age-adjusted incidence rate is approximately 2.0 cases per 100000 people every year that 
increase with age, average age, average age at diagnosis is around 65, and is higher in men 
than in women (3). CML is typically associated with a balanced reciprocal translocation 
between the long arms of chromosomes 9 and 22 or t(9;22) resulting to a shortened 
chromosome 22  (Philadelphia chromosome). This translocation is named Philadelphia 
chromosome (Ph), and was first reported in 1960 by Peter Nowell and David Hungerford 
in the chromosomes from cultured blood cells of two patients with CML (4). The Ph 
chromosome (BCR-ABL fusion gene) is formed by fusion of the 3´ sequences from ABL1 
(Abelson) gene at 9q34 to the 5´ portion of the BCR (breakpoint cluster region) gene 
sequences at 22q11. The product of this fusion BCR-ABL gene is a constitutively active 
protein tyrosine kinase, p210 BCR-ABL, that promotes cellular proliferation and 
suppresses apoptosis.     
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BCR-ABL kinase activity is critical to the development 
of CML (5). Although BCR-ABL fusion gene can be 
detected in all CML patients at the molecular level; it is not 
limited to CML. This balanced translocation may also be 
seen in other malignancies such as acute lymphoblastic 
leukemia and occasionally in newly diagnosed acute myeloid 
leukemia (AML) (6-9).  
The BCR gene has 23 exons (e1 to e23) and the ABL 
gene has 12 exons (1b; 1a; a2 to a11). The breakpoints 
within the ABL gene (at 9q34) occur in a nearly constant 
region. In CML, breakpoint in this gene is variable over a 
region of about 300 kb at the 5' end of the ABL gene and 
often between the two alternative exons 1b and 1a (always 5' 
of exon 2). In CML, the breakpoints within the BCR gene 
are localized to one of three main regions. The commonest is 
the major breakpoint cluster region, (M-BCR), a cluster of 
5.8 kb within BCR exons 12 and 16, also called b1 to b5. 
Generally, the break occurs within introns located between 
exons b2 and b3 or b3 and b4 with the exon a2 forming the 
fusion gene b2a2 or b3a2, respectively. A 210-kd chimeric 
protein is derived from this mRNA (P210). The second 
groups of breakpoints occur in the 54.4-kb region between 
the alternative BCR exons e2' and e2 region, termed the 
minor breakpoint cluster region (m-bcr). The resultant e1a2 
mRNA is translated into a 190-kd protein (P190). Due to 
alternative splicing, a small amount of P190 may be found in 
many CML patients. The third breakpoint cluster region (µ-
bcr) is identified between BCR exons 19 and 20 
(downstream of exon 19). The resultant e19a2 mRNA is a 
230-kd fusion protein (P230) (10-12). 
Detection of BCR-ABL1 fusion transcript variants may 
have clinical importance. De Lemos et al. showed that B2A2 
may be more sensitive to imatinib than b3a2 and concluded 
that CML patients who express the B2A2 may have a better 
prognosis (13). There are some studies about relationship 
between ela2 and prominent monocytosis (14); and high 
platelet counts and also marked splenomegaly have been 
reported in CML patients with coexpression of the 
p190/p210 (15). This study was done to determine the 
frequency of BCR-ABL fusion genes and laboratory findings 




This cross-sectional study was performed on 85 cases of 
CML referred by hematologists to molecular pathology 
laboratory of Ghaem Hospital, Mashhad, Iran in 2012-2013. 
The study was approved by local ethics committee and also 
financially supported by the Research Vice Chancellery of 
Mashhad University of Medical Sciences. All patients had 
clinical, complete blood count (CBC), peripheral blood 
smear (PBS) and bone marrow (BM) features of CML such 
as splenomegaly, leukocytosis, eosinophilia, basophilia, 
neutrophilia, 1-10% blasts in PBS or BM. Diagnosis of CML 
was done according to WHO criteria (1). Patients with 
incomplete criteria for diagnosis of CML were excluded.  
For each patient, five to ten milliliter anticoagulated 
peripheral blood (with ethylenediaminetetraacetic acid, 
EDTA-K2) or 0.5-1 ml of bone marrow aspiration was 
drawn and then RNA was extracted by RNeasy Mini kit 
(Qiagen, Valencia, CA) according to the manufacturer's 
instruction.  
RNA concentration was determined applying the Thermo 
Scientific NanoDrop 2000 Spectrophotometer and specimens 
with low RNA content (<20 ng/µL) were excluded from the 
study. After that, cDNA was synthesized by cDNA synthesis 
kit (Fermentas UAB, Lithuania). Finally, PCR for BCR-ABL 
was achieved by nested PCR with a set of external primers 
(A& B) and internal primers (C&D) as follows:   
BCR-ABL p190 fusion gene,  
BCR-e1-A 5´-GACTGCAGCTCCAATGAGAAC- 3 ´, 
 ABL-a3-B 5´-GTTTGGGCTTCACACCATTCC-3´,  
BCR-e1-C 5´-CAGAACTCGCAACAGTCCTTC-3´, 
 BCR-e3-D 5´-CAGAACTCGCAACAGTCCTTC-3´ 
BCR-ABL p210 fusion gene,  
BCR-b1-A 5´-GAAGTGTTTCAGAAGCTTCTCC-3´,  
ABL-a3-B 5´-GTTTGGGCTTCACACCATTCC-3´, 
 BCR-b2-C 5´-CAGATGCTGACCAACTCGTGT-3´ 
ABL-a3-D 5´-TTCCCCATTGTGATTATAGCCTA-3´ 
ABL Control gene: ABL-F 5´-CCT TCA GCG GCC AGT AGC-3´ 
ABL-R    5´-GGA CAC AGG CCC ATG GTA C-3´ 
PCR was performed in total volume of 25µL by adding 
2-3 µL of cDNA, 1U/ µL Taq enzyme, 200µM dNTP, 2.5 
Mm Mgcl2, 400 nmol of each primers, 20 mM Tris HCL , 
50 mM KCL (pH=8.3) and distilled water. For the second 
round, PCR 1 µL of first round PCR products were added.                 
cDNA synthesized from K562 cells (b3a2) and KCL22 
for  b2a2 cells type and  ALL/MIK for p190 e1a2 were used 
as positive controls and sterile water was used as negative 
controls. In this study, we used ABL gene as a control gene. 
The tubes were placed into Applied Biosystem (ABI) Veriti 
Thermal Cycler and PCR was started with 30 seconds at 
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o
C for the first step and then 35 cycles was run as follows: 
30 seconds at 94°C, 60 seconds at 65°C, 60 seconds at 72°C 
and final extension was 10 min at 72
o
C. Products were 
electrophoresed on a 2% agaros gel with robust DNA stain. 
Bands of 521 bp ,417 bp, 342 and 340 bp were observed for 
e1-a2, b3-a2,b2-a2 and normal ABL, respectively, for first 
round PCR and bands of 381 bp ,360 bp ,285 bp and 282 bp 
were detected e1-a2, b3-a2,b2-a2 and normal ABL, 
respectively, in second nested PCR, respectively. Statistical 
analysis: RT-PCR (PCR results) and other laboratory 
findings were analyzed with SPSS Version 11.5. We used 
Pearson’s chi-square test for comparison of categorical 
variables and independent sample t-test and Mann-Whitney 
test for continuous variables between the case and the control 
groups. A p-value below 0.05 was considered significant. 
Results  
P210 BCR/ABL rearrangements (b2a2 and b3a2) were 
more common than P190 (e1a2). Fusion of b3a2 was 
detected in 53 (62.35%) patients, b2a2 in 25 (29.41%), e1a2 
in 1 (1.17%) and both b3a2 and e1a2 in 6 patients (7.05%). 
Patients' age range and mean age (±SD) were 21 to 77 years 
and 45.89±15.60 years, respectively.  
There was no significant difference between b2a2 
(P=0.095) positive and negative groups and also between 
e1a2 (P=0.48) positive and negative groups for mean age of 
patients.  
The mean age (±SD) in patients with b3a2 positive was 
44.07(±SD) years and in b3a2 negative group was 50.35 
(±SD)years and Mann-Whitney test showed a significant 
difference between these two groups (P=0.046).  
 
Table 1. Comparing CBC, peripheral blood smear and biochemical findings in b3a2, b2a2 and e1a2 positive and negative 
patients 
e1a2 b2a2 b3a2 Variables 
Pvalue Positive Negative Pvalue Positive Negative Pvalue Positive Negative  
 Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD 
0.22 3.2±0.8 3.5±0.7 0.78 3.5±0.6 3.5±0.7 0.94 3.5±0.7 3.5±0.6 RBC x 1012 /L 
0.35 153.9±72.1 131.9±58.8 0.89 135.1±43.7 133.1±65.7 0.98 133.6±66.2 133.9±43.2 WBC x 109 /L 
0.14 518.1±623.6 368.3±206.2 0.39 343.1±233.2 396.3±273.0 0.26 401.7±272.1 333.0±234.3 PLT x 109 /L 
0.29 29.4±6.8 31.8±5.7 0.35 32.5±5.1 31.2±6.1 0.59 31.3±6.0 32.1±5.4 HCT (L/L) 
0.20 9.4±1.9 10.3±1.8 0.15 10.6±1.5 10.0±1.9 0.36 10.1±1.8 10.5±1.7 HGB (mg/dL) 
0.67 90.8±5.2 89.4±8.3 0.09 91.8±9.7 88.6±7.2 0.10 88.6±7.2 91.7±9.5 MCV (fL) 
0.99 29.2±3.0 29.3±4.1 0.11 30.3±4.7 28.8±3.7 0.16 28.8±3.7 30.2±4.7 MCH (Pg) 
0.77 32.2±2.85 32.5±2.8 0.39 32.9±2.3 32.3±2.9 0.53 32.3±2.9 32.8±2.3 MCHC(mg/dL) 
0.06 8.9 ±7.3 3.6±4.1 0.56 3.6±4.2 4.3±5.7 0.99 4.1±5.5 4.1±4.8 Blast % 
0.84 6.4±3.1 6.6±3.1 0.38 6.2±3.5 6.8±2.9 0.25 6.9±2.9 6.0±3.4 Eosinphils % 
0.14 5.5±2.1 7.7±3.9 0.14 6.6±3.4 7.9±3.9 0.09 8.0±3.9 6.5±3.4 Basophils % 
0.26 39.7±7.8 44.2±10.3 0.01̽ 48.5±10.0 41.8±9.7 0.05 42.1±9.5 48.7±9.8 Neutrophils % 
0.93 25.2±11.7 25.0±6.6 0.11 23.2±7.2 25.8±6.9 0.07 26.0±6.7 22.8±7.4 Myelocyte % 
0.95 10.4±12.9 6.0±3.9 0.54 5.8±3.2 6.6±5.9 0.82 6.1±4.4 7.0±6.8 Monocytes % 
0.48 41.8±14.9 46.2±15.7 0.47 36.5±20.4 49.8±43.2 0.47 49.8±43.2 36.5±20.4 Urea (mg/dL) 
0.22 3.2±0.8 3.5±0.7 0.31 1.0±0.5 1.6±1.2 0.31 1.6±1.25 1.0±0.5 Creatinine(mg/dL) 
0.35 153.9±72.1 131.9±58.8 0.96 141.0±5.8 140.8±4.4 0.96 140.8±4.4 141.0±5.85 Sodium 
0.14 518.1±623.6 368.3±206.2 0.70 4.2±0.4 4.3±0.6 0.70 4.3±0.6 4.2±0.46 Potassium 
0.29 29.4±6.8 31.8±5.7 0.99 9.4±0.98 9.4±0.2 0.99 9.4±0.2 9.4±0.98 Calcium 
0.20 9.4±1.9 10.3±1.8 0.09 8.7±3.3 5.7±1.3 0.09 5.7±1.3 8.7±3.3 Uric acid 
0.67 90.8±5.2 89.4±8.3 0.96 2315.0±1926.0 2360.4±964.1 0.96 2360.4±964.1 2315.0±1926.0 LDH 
0.99 29.2±3.0 29.3±4.1 0.25 33.2±15.5 19.0±14.7 0.25 19.0±14.7 33.2±15.5 AST 
0.77 32.2±2.85 32.5±2.8 0.35 23.6±14.6 14.6±3.2 0.35 14.6±3.2 23.6±14.6 ALT 
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Forty-one (48.2%) patients were male and 44 (51.8%) 
patients were females. Pearson’s chi-square test showed no 
significant difference between sex and b2a2 (P=0.61), b3a2 
(P=0.79) and e1a2 (P=0.20). Splenomegaly was present in 
52 (61.2%) patients and hepatomegaly in 24 (28.2%). 
Although splenomegaly and hepatomegaly were more 
common in the p210 positive group than the negative group, 
these differences were not significant (P=0.06% and 
P=0.08%, respectively) Nine (10.6%) patients (5 males and 4 
females) were in accelerated phase and 76 (89.4%) patients 
in chronic phase of CML.  
There was not any significant differences between 
different phases of CML (accelerated or chronic) and kind of 
BCR/ABL fusion (P=0.22), sex (P=0.64) and patients’ age 
(P=0.15); however, patients’ age in accelerated phase 
(52.89±16.09 years) was more than the chronic phase 
(45.07±15.44 years).  
Table 1 shows the laboratory findings of CML patients 
and compare the positive and negative BCR/ABL fusion 
results. Neutrophil precentage in b3a2, b2a2 and e1a2 




In our study, b3a2 transcripts were more frequent than 
b2a2 (62.35% vs 29.41%). This finding is concordant with 
the studies of Todoric-Zivanovic et al. (16), Bennour et al. 
(17) and Anand et al. (18) nevertheless by contrast, in the 
studies of Arana-Trejo et al. (15), Rosas-Cabral et al. (19) 
and Muddathir et al. (20). In a study by Todoric-Zivanovic et 
al. in Siberia b3a2 was reported in 74%, b2a2 in 25.0% and 
b3a2 / e1a2 in one (1%) (16) patient. Another study by 
Bennour et al. in Tunisia, CML patients showed that more 
than half of them had b3a2 fusion transcript (64 %), almost 
one third (36 %) b2a2 transcript, nonetheless, coexpression 
of b3a2 and b2a2 was not detected in any patients. (17). 
Anand et al. (18) demonstrated b3a2 in 67%, b2a2 in 29% , 
b3a2/ b2a2  in 4%, b3a2/e19a2 in 0.5% and b2a2/e19a2 in 
0.5% in India. Arana-Trejo et al. (15) found b3a2 in 35%, 
b2a2 in 48%, and both b3a2 and b2a2 in 3% in Mexico. 
Rosas-Cabral et al. (19) detected b3a2 bcr-abl in 28% cases, 
b2a2 in 59% cases, and 13% with both b3a2 and b2a2 in 
Spanish patients; while Muddathir et al. (20) reported b3a2 
bcr-abl transcripts in 21 patients, b2a2 in 6 cases, and 8 
patients with both b3a2/b2a2 in Sudanese patients. 
Coexpression of different transcriptants may occur due to 
change in the phenotype of   the leukemic cells and also due 
to alternative splicing of mRNA. The co-expressed 
p190/p210 transcript frequencies in our CML (7.05%) 
patients were similar in Mexican population (5%) and were 
less frequent than the Sudanese population (17.4%) (15, 19). 
Furthermore, marked splenomegaly and high platelet counts 
in coexpressed p190/ p210 patients were reported by Arana-
Trejo (15)  although we did not find a significant difference 
for p190/p210 transcripts and platelet count (p=0.12) and 
also in the relationship between  p190/p210 transcripts  and 
splenomegaly (p=0.13). Similar to our study, Yaghmaie et al. 
did not find any significant differences between clinical 
findings in CML patients and BCR-ABL breakpoints (23). 
In our study, the patients with b2a2 were older than the 
patients with b3a2 transcripts, yet there was not significance 
(p=0.16). This finding was statistically significant in the 
study by Bennour et al. (17). Male to female ratio in our 
study was 29/30 for b3a2, 11/14 for b2a2 and 5/2 for e1a2; 
and Goh et al. (21) and Bennour et al. (17). Our study did not 
reveal the significant differences between sex and b2a2 
(p=0.61), b3a2 (p=0.79) or e1a2 (p=0.20). Despite that, high 
male to female ratio for b2a2 (15.8) and low ratio for b2a2 
(5/13) have been reported by Osman et al. (22). 
Inspite of the association between P190 with peripheral 
blood monocytosis in CML has been reported (14), our 
results did not show any relationship between e1a2 transcript 
frequencies and (p=0.95) and absolute monocyte count 
(p=0.58). Notwithstanding, our results showed higher 
neutrophil percentage in the b3a2 and b2a2 positive groups, 
in the negative groups absolute neutrophilic count (p=0.27 
for b3a2 and p=0.25 for b2a2) was not significant. Small size 
population was one of present study’s limitations and it is 
better to to conduct it in large population; another limitation 
was the lack of access to patients for follow-up and calculate 
survival markers to determine BCR-ABL fusion transcribe. 
In conclusion, the results of our study showed higher 
frequency b3a2 than b2a2 and e1a2 transcripts in CML 
patients in Northeast Iran. The mean age in patients with 
b3a2 positive was younger than b3a2 negative group and 
neutrophil percentage in the b3a2 and b2a2 positive groups 
was higher than the b3a2 and b2a2 negative groups. There 
was no association between e1a2 transcript frequencies, 
percentage of monocytes and absolute monocytic count in 
PBS.  
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